Viva Biotech Holdings 1873

On August 26, 2026, Viva Biotech Holdings Group ("the Group" or "the Company", stock code: 1873.HK) announced that the Group's revenue amounted to RMB1,006.5 million and gross profit of RMB341.7 million, representing a gross margin of 34.0%. Overall, the Group's total revenue grew by approximately 21.0% year-on-year, primarily driven by the significant contribution from Langhua Pharmaceutical's CDMO business, under which one peptide project has entered the commercial production phase and the oth

On May 20, 2026, Viva Biotech hosted a V-Experts in Conversation webinar, "Managing Complexity in Modern Drug Discovery: A Practical Approach to Integrated Screening & Chemistry." Moderated by Victoria Ouroutzoglou, Associate Director of Business Development at Viva Biotech, the roundtable featured Dr. Bing Xia, Vice President & Head of Early Discovery Platforms, and Dr. Tim Dwight, Senior Director of Medicinal Chemistry & Business Development. The discussion examined how integrated screening wo

As drug discovery places greater emphasis on practical execution and scalable delivery, flow chemistry is playing an increasingly important role across modern synthesis workflows. At the latest Viva Biotech's series webinar, "AI x Flow Chemistry: From Bench to Business — Academic and Industry Perspectives," Viva Biotech brought together speakers from academia and industry to discuss how flow chemistry is reshaping synthesis, automation, and scale-up. Inviting Dr. Jie Wu of the National Universit

On March 30, 2026, Viva Biotech Holdings ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that for the Group's revenue amounted to RMB1,729.4 million during the Reporting Period, with gross profit of RMB655.6 million. The Group's gross profit margin was 37.9%, representing an increase of 3.3 percentage points compared with the same period last year, mainly attributable to the optimization and adjustment of Langhua Pharmaceutical's business mix, improved operational e

As global markets navigate a complex landscape marked by economic uncertainties and shifting monetary policies, Asian small-cap stocks are capturing attention for their potential resilience and growth. In this environment, identifying promising opportunities requires a keen eye for companies with strong fundamentals and the ability to adapt to changing market conditions.